You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here

Complete-PS

Canadian HUMIRA Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

    Status Recruitment completed
    Related Conditions
    Psoriasis

Enrollment Details

662 Worldwide Enrollment Goal

Phases: 

  • 1
  • 2
  • 3
  • 4
Study Type:  Observational

This is a type IV phase trial.

Protocol ID
P12-678

Brief summary

Top

The current study will compare the real-life effectiveness of adalimumab to topical and traditional systemic agents in the management of psoriasis and its impact on the patient's quality of life and societal burden of illness.

Participant Attributes :
  • Male and Female
  • Ages 18 Years to 99 Years

Canada: 36

0
Calgary, AB
1
Calgary, AB
2
Calgary, AB
3
Edmonton, AB
4
Edmonton, AB
5
Nanaimo, BC
6
Victoria, BC
7
Brandon, MB
8
Winnipeg, MB
9
Bathurst, NB
10
Fredericton, NB
11
Moncton, NB
12
Quispamsis, NB
13
St. John's, NL
14
St. John's, NL
15
Halifax, NS
16
Barrie, ON
17
Etobicoke, ON
18
Hamilton, ON
19
London, ON
20
Markham, ON
21
Mississauga, ON
22
Mississauga, ON
23
Oakville, ON
24
Peterborough, ON
25
Richmond Hill, ON
26
St-Catharines, ON
27
Sudbury, ON
28
Thornhill, ON
29
Toronto, ON
30
Drummondville, QC
31
St-Jérôme, QC
32
Pierrefonds, QC
33
Verdun, QC
34
Westmount, QC
35
Saskatoon, SK
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.
    ?

    Observational Model

    Cohort

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
    ?

    Time Perspective

    Prospective

    • Active moderate or severe Plaque PS according to the judgment of the treating physician.
    • The treating physician has decided to change the current treatment or add additional treatments for any reason including but not limited to inadequate response, intolerance, sub-optimal compliance or patient preference.

     

    • Currently participating in another prospective study with similar objectives.
    • Patient cannot or will not sign informed consent.
    • Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Plaque PS.

More on this trial

Clinical Trials.gov